SARS-CoV2 might conduce to rapid respiratory complications challenging healthcare systems worldwide. Immunological mechanisms associated to SARS-CoV2 infection are complex and not yet clearly elucidated. Arguments are in favour of a well host-adapted virus. Here I draw a systemic immunological representation linking actual SARS-CoV2 infection literature that hopefully might guide healthcare decisions to treat COVID-19. I suggest HLA-G and HLA-E, non classical HLA class I molecules, in the core of COVID-19 complications. These molecules are powerful in immune tolerance and might inhibit/suppress immune cells functions during SARS-CoV2 infection promoting virus subversion. Dosing soluble forms of these molecules in COVID-19 patients’ plasma might help the identification of critical cases. I recommend also developing new SARS-CoV2 therapies based on the use of HLA-G and HLA-E or their specific receptors antibodies in combination with FDA approved therapeutics to combat efficiently COVID-19.

SARS-CoV2可能导致快速的呼吸系统并发症，挑战了全球医疗系统。与SARS-CoV2感染相关的免疫机制很复杂，尚不清楚。论据支持宿主适应性良好的病毒。在这里，我绘制了一个系统的免疫学表示法，将实际的SARS-CoV2感染文献联系起来，希望可以指导医疗保健决策以治疗COVID-19。我建议将非经典HLA I类分子HLA-G和HLA-E置于COVID-19并发症的核心。这些分子具有强大的免疫耐受性，并可能在SARS-CoV2感染过程中抑制/抑制免疫细胞的功能，从而促进病毒的颠覆。在COVID-19患者的血浆中服用这些分子的可溶形式可能有助于识别危重病例。